Exclusive Summary

• - No patent barrier and WHO EML inclusion, with the widely used 600 mg strength enabling rapid registration and tender access across countries.
• - High and persistent demand driven by hypokalemia in inpatients (≈7–20%) and diuretic users (≈10–40%), on top of large global cardio‑renal patient pools.
• - Oral sustained‑release KCl is first‑line for mild–moderate hypokalemia and diuretic‑related prevention, reducing GI irritation and improving adherence.
• - Fragmented global competition with uneven supply quality; CTD/BE and Zone IVb stability provide clear tender and market‑access advantages.
• - 60–90% cost reduction versus brands, with both 0.5 g and 0.6 g strengths (6.7/8 mmol) matching diverse dosing practices to maximize coverage and win‑rate.